Erbitux Phase IV Trials To Study EGFR-Negative Populations
Bristol-Myers Squibb and ImClone's post-approval commitments include an examination of the efficacy of Erbitux in patients with EGFR-negative colorectal cancer
Bristol-Myers Squibb and ImClone's post-approval commitments include an examination of the efficacy of Erbitux in patients with EGFR-negative colorectal cancer